Loading patent…
AssigneeBoehringer Mannheim GmbH
InventorsChristos Tsaklakidis, Elmar Bosies, Angelika Esswein, Frieder Bauss
Estimating the term…
Compounds of the formula I ##STR1## in which R signifies a possibly substituted amino group of the general formula --NR.sup.1 R.sup.2, whereby, independently of one another, R.sup.1 and R.sup.2 each signify hydrogen, lower alkyl, lower alkenyl or lower alkynyl or R represents a saturated, unsaturated or aromatic heterocyclic ring which can possibly be substituted once or twice by lower alkyl or halogen, alk signifies a valency bond, a methylene, a saturated or unsaturated, straight-chained or branched alkylene chain with 2-6 carbon atoms and R.sup.3, R.sup.4 and R.sup.5, in each case independently of one another, signify hydrogen, lower alkyl or benzyl, as well as their pharmacologically acceptable salts and enantiomers, whereby, for the case that R.sup.3 =R.sup.4 =R.sup.5 =CH.sub.3 and alk signifies a valency bond, R cannot be the dimethylamino group, processes for their preparation and medicaments which contain these compounds for the treatment of calcium metabolism diseases.
A phosphonosuccinic acid compound of the formula ##STR15## wherein:
A pharmaceutical composition suitable for the treatment of calcium metabolism disturbances comprising a compound of the formula ##STR16## wherein R is a nitrogen atom containing heterocyclic ring selected from the group consisting of aziridine, azetidine, and pyrrolidine, wherein the heterocyclic ring is unsubstituted or substituted once or twice by C.sub.1 -C.sub.6 alkyl or halogen;
A method of treating a calcium metabolism disturbance in a patient in need of such treatment, said method comprising administering to said patient a calcium metabolism disturbance-treating amount of a compound of the formula ##STR17## wherein:
Dependencies are inferred from the claim text.